Marcel Deckert
Overview
Explore the profile of Marcel Deckert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Sanchez J, Bonnet E, Loubatier C, Doye A, Paillier G, Segui F, et al.
iScience
. 2025 Feb;
28(2):111838.
PMID: 39995862
Transcription factor EB (TFEB) is a key transcription factor that orchestrates the cellular response to stress. Dysregulation of TFEB is associated with a range of human diseases, and understanding the...
2.
Rabhi B, Thomasseau S, Decrouy X, Cohen-Solal M, Deckert M, Coudert A, et al.
PLoS One
. 2025 Feb;
20(2):e0318826.
PMID: 39951467
Cherubism is a rare genetic disorder caused by SH3BP2 mutations. This sterile autoinflammatory disease is characterized by jaw osteolysis, in which bone tissue is replaced by multinucleated giant cells containing...
3.
Iberti M, Loschi M, Keslair F, Deckert M, Pichery E, Di Mauro I, et al.
Ann Hematol
. 2025 Feb;
PMID: 39923209
Chronic eosinophilic leukemia (CEL) is a rare myeloproliferative neoplasm. Diagnosis of CEL is often challenging, notably because of the lack of recurrent and specific molecular event. We report here a...
4.
Sirera J, Sarlak S, Teisseire M, Carminati A, Nicolini V, Savy C, et al.
J Exp Clin Cancer Res
. 2024 Dec;
43(1):335.
PMID: 39736693
Background: Multiple Myeloma (MM) is the second most common hematological malignancy, characterized by the accumulation of monoclonal plasmocytes in the bone marrow. Despite advancements with proteasome inhibitors, immunomodulatory agents, and...
5.
Chelli M, Descamps J, Lavoue V, Trojani C, Azar M, Deckert M, et al.
J Med Internet Res
. 2024 May;
26:e53164.
PMID: 38776130
Background: Large language models (LLMs) have raised both interest and concern in the academic community. They offer the potential for automating literature search and synthesis for systematic reviews but raise...
6.
Diazzi S, Tartare-Deckert S, Deckert M
Oncogenesis
. 2023 Feb;
12(1):7.
PMID: 36774337
Advanced cutaneous melanoma is the deadliest form of skin cancer and one of the most aggressive human cancers. Targeted therapies (TT) against BRAF mutated melanoma and immune checkpoints blockade therapies...
7.
Ruetsch-Chelli C, Okuda D, Rocher F, Tartare-Deckert S, Deckert M, Lebrun-Frenay C
Neurol Ther
. 2022 Dec;
12(1):289-302.
PMID: 36534273
Introduction: S1P receptor modulators (S1P-RM) are oral disease-modifying therapies (DMTs) for multiple sclerosis (MS). Several authorities have raised doubts that S1P-RM are responsible for an increased risk of melanoma in...
8.
Ohanna M, Biber P, Deckert M
Cancers (Basel)
. 2022 Jul;
14(14).
PMID: 35884430
Metastatic melanoma is the leading cause of death from skin cancer. Therapies targeting the BRAF oncogenic pathway and immunotherapies show remarkable clinical efficacy. However, these treatments are limited to subgroups...
9.
Rovera C, Berestjuk I, Lecacheur M, Tavernier C, Diazzi S, Pisano S, et al.
Cancer Res
. 2022 May;
82(9):1774-1788.
PMID: 35502542
Significance: Communication between dedifferentiated melanoma cells and lymph node fibroblasts reprograms the biomechanical properties of the premetastatic lymph node niche to promote tumor invasion. See related commentary by Lund, p....
10.
Diazzi S, Baeri A, Fassy J, Lecacheur M, Marin-Bejar O, Girard C, et al.
EMBO Mol Med
. 2022 Feb;
14(3):e15295.
PMID: 35156321
Lineage dedifferentiation toward a mesenchymal-like state displaying myofibroblast and fibrotic features is a common mechanism of adaptive and acquired resistance to targeted therapy in melanoma. Here, we show that the...